JavaScript is Disabled
Your browser's JavaScript functionality is disabled. It has to be enabled to use this function of ConfTool.
Here you can find information on how to enable JavaScript
If you have any problems, please contact the organizers at parasitologycommunicator@gmail.com.

Conference Agenda

Overview and details of the sessions of this conference. Please select a date or location to show only sessions at that day or location. Please select a single session for detailed view (with abstracts and downloads if available).

Daily Overview

Session

CP5.1: Immunology 1 - 10 min talks
Location: Lecture Theatre 2
Session Chair: Danielle Stanisic, Institute for Biomedicine and Glycomics, Griffith University
Session Chair: Hannah Siddle, The University of Queensland

Presentation 3

Impact of HIV infection on malaria antibody responses induced by the RTS,S vaccine or naturally acquired in adults

Grace Wright^1,2, Liriye Kurtovic^1,2,3, D. Herbert Opi^1,2,3, Cythia Lee⁴, Chris Ockenhouse⁴, Emily Locke⁴, Lucas Otieno⁵, Nate Copeland⁵, NCT04661579 Clinical Trial Team^4,5, James G. Beeson^1,2,3

1: Burnet Institute, Melbourne, Australia; 2: Department of Infectious Diseases, University of Melbourne, Melbourne, Australia; 3: Central Clinical School and Department of Microbiology, Monash University, Melbourne, Australia; 4: Centre for Vaccine Innovation and Access, PATH, Washington DC, USA; 5: Kombewa Clinical Research Centre, Kenya Medical Research Institute, Kisumu, Kenya

Plasmodium falciparum malaria remains a major global health burden. Co-infection with HIV, common among adults in malaria endemic regions, increases susceptibility to malaria and disease severity. However, the impact of HIV on vaccine induced and naturally acquired malaria immunity remains poorly understood. We evaluated a cohort of Kenyan adults naturally exposed to malaria who were vaccinated with the RTS,S malaria vaccine as part of a phase-IIb clinical trial. Individuals were either HIV-negative (n=204) or HIV-positive (n=45) at baseline. Using a multi-antigen multi-functional assay platform, we quantified antibody responses (IgG, Fc-receptor binding and complement fixation) to 35 malaria antigens, including the RTS,S vaccine antigen CSP, in plasma samples collected 28 days after vaccination. There was no difference in CSP IgG responses, including functional activities between HIV-negative and HIV-positive individuals. However, IgG and functional antibody responses to a majority of the non-vaccine malaria antigens were significantly higher in HIV-negative compared to HIV-positive individuals. HIV infection was associated with widespread impairment in the acquisition of naturally acquired malaria immunity, but did not substantially impact RTS,S vaccine induced immunity. Our findings suggest that malaria vaccines could provide benefit to HIV-positive people who have impaired acquired immunity and are at a higher risk of malaria.